ROIV - Roivant Sciences Ltd. Stock Price, Fair Value and News

$20.69+0.59 (+2.94%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

ROIV Price Action

Last 7 days

-0.9%

Last 30 days

5.6%

Last 90 days

64.6%

Trailing 12 Months

70.7%

ROIV RSI Chart

ROIV Valuation

Market Cap

14.4B

Price/Earnings (Trailing)

-41.22

Price/Sales (Trailing)

3.24

EV/EBITDA

-15.29

Price/Free Cashflow

-18.35

ROIV Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

ROIV Fundamentals

ROIV Revenue

Revenue (TTM)

4.5B

Rev. Growth (Yr)

-97.25%

Rev. Growth (Qtr)

-30.74%

ROIV Earnings

Earnings (TTM)

-349.1M

Earnings Growth (Yr)

59.45%

Earnings Growth (Qtr)

49.18%

ROIV Profitability

EBT Margin

-19.05%

Return on Equity

-7.26%

Return on Assets

-6.9%

Free Cashflow Yield

-5.45%

ROIV Investor Care

Buy Backs (1Y)

4.46%

Diluted EPS (TTM)

-0.56

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	0	0	0	0
2024	4.5B	0	0	0
2023	61.3M	73.7M	75.4M	4.7B
2022	55.3M	51.9M	50.4M	43.1M
2021	23.8M	30.0M	42.6M	61.2M
2020	67.7M	56.7M	45.7M	34.8M

Get all data in R, Python etc through our Historical Stock Data APIs

About Roivant Sciences Ltd.

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

CEO	Mr. Matthew Gline
WEBSITE	https://roivant.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	904

Roivant Sciences Ltd. Frequently Asked Questions

What is the ticker symbol for Roivant Sciences Ltd.? What does ROIV stand for in stocks?

ROIV is the stock ticker symbol of Roivant Sciences Ltd.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Roivant Sciences Ltd. (ROIV)?

As of Wed Dec 03 2025, market cap of Roivant Sciences Ltd. is 14.39 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ROIV stock?

You can check ROIV's fair value in chart for subscribers.

Is Roivant Sciences Ltd. a good stock to buy?

The fair value guage provides a quick view whether ROIV is over valued or under valued. Whether Roivant Sciences Ltd. is cheap or expensive depends on the assumptions which impact Roivant Sciences Ltd.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ROIV.

What is Roivant Sciences Ltd.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, ROIV's PE ratio (Price to Earnings) is -41.22 and Price to Sales (PS) ratio is 3.24. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ROIV PE ratio will change depending on the future growth rate expectations of investors.